Home > Boards > US Listed > Biotechs >

Aptevo Therapeutics Inc. (APVO)

Add APVO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/25/2021 7:15:00 PM - Followers: 9 - Board type: Free - Posts Today: 0

SEATTLE--(BUSINESS WIRE)--August 01, 2016-- Aptevo Therapeutics Inc. ("Aptevo"; "the Company") (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has reached agreement with MidCap Financial on the final terms on a $35 million term loan. The agreement provides Aptevo with up to $35 million of available borrowing capacity, which will be available to the Company in two tranches of $15 million to $20 million, at the Company's discretion, through January 2021. The agreement bears interest at a rate of LIBOR plus 7.60% per annum. The parties expect to close the transaction at the end of the week, provided certain closing conditions are met. The Company expects to draw the first tranche in August 2016, and will be able to access the second tranche after the Company achieves net commercial products revenue of $40 million on a trailing twelve month basis and receives the $20 million balance of the Emergent BioSolutions cash injection. This $20 million amount is secured by a non-negotiable, unsecured promissory note and will be received within six to 12 months of the separation. Marvin White, President and Chief Executive Officer of Aptevo, stated: "We are pleased to partner with MidCap Financial on this agreement. We believe this financing, along with the $65 million total cash contribution from Emergent BioSolutions and the cash flows generated from our commercial product portfolio, provide Aptevo with a solid cash position to pursue our strategy of bringing novel oncology and hematology therapeutics to market in order to enhance patients' lives and drive value for our shareholders." About Aptevo Therapeutics Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives. Its core technology is the ADAPTIR(TM) (modular protein technology) platform. Aptevo has four revenue-generating products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology. Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the potential opportunities and financial impact of the transaction, our technology and related pipeline, collaboration and partnership opportunities and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; adverse developments in our customer-base or markets; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including our Registration Statement on Form 10, as amended. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005439/en/ CONTACT: Aptevo Therapeutics Stacey Jurchison, 206-859-6628 Senior Director, Investor Relations and Corporate Communications JurchisonS@apvo.com SOURCE: Aptevo Therapeutics Copyright Business Wire 2016 (END) Dow Jones Newswires August 01, 2016 07:30 ET (11:30 GMT) Story ID: 20160801SN005400 Keywords: COMPANY NEWS, THIRD-PARTY CONTENT, PRESS RELEASES AUTO-PUBLISHED ON TICKER, DOW JONES CONTENT SET SN, GRAND CENTRAL ASSET CLASS EQUITIES, PRESS RELEASES ON NEWSWIRES, HEALTH, BUSINESS WIRE, SIGNIFICANT STORY, HEALTH CARE, GENERAL NEWS, PRESS RELEASE WIRES, BIOTECHNOLOGY Symbols: APVO
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APVO News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 03:14:38 PM
APVO News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 02:52:37 PM
APVO News: Amended Statement of Ownership (sc 13g/a) 02/12/2021 05:31:34 PM
APVO News: Amended Statement of Ownership (sc 13g/a) 02/12/2021 09:26:27 AM
APVO News: Amended Statement of Ownership (sc 13g/a) 02/11/2021 06:09:53 AM
#82   Anyone still holding this? Dartgator 02/25/21 07:15:00 PM
#81   Breaking News: $APVO Aptevo Confirms Receipt of Unsolicited whytestocks 11/19/20 04:45:22 PM
#80   WOW. I LOVE TANG CAPITAL. TANG SUBMITS PROPOSAL otcmoneydoubler 11/18/20 05:22:57 PM
#79   APVO AND PSHG ALL DAY. WATCHING AHT HOSPITALITY RALLY. otcmoneydoubler 11/11/20 09:14:35 AM
#78   JUST IN: $APVO Aptevo Therapeutics Reports Third Quarter whytestocks 11/10/20 05:00:18 PM
#77   LJPC is next. Follow the money rusty8350 11/09/20 04:55:11 PM
#76   BREAKING NEWS: $APVO Aptevo Therapeutics to Present at whytestocks 11/09/20 11:30:26 AM
#75   NEWS: $APVO Biotech Brief: Breast Cancer Drug Market whytestocks 11/09/20 11:15:19 AM
#74   BREAKING NEWS: $APVO Aptevo Therapeutics Announces Second Complete whytestocks 11/09/20 11:00:24 AM
#73   BREAKING NEWS: $APVO Aptevo Therapeutics Adopts Limited Duration whytestocks 11/08/20 11:45:23 PM
#72   "bispecific technologies may represent a simpler, more competitive crudeoil24 11/08/20 08:58:48 PM
#71   Of course probably, and just my freaking luck, trendzone 11/07/20 03:46:12 PM
#70   $APVO : Did this just hit $88 AH makinezmoney 11/06/20 07:22:24 PM
#69   APVO TANG OWNERSHIP Filings ah https://whalewisdom.com/filer/tang-capital-partners-lp [SMART MONEY] 11/06/20 05:34:57 PM
#68   * * $APVO Video Chart 11-05-2020 * * ClayTrader 11/05/20 05:26:46 PM
#67   Looks like their loading up on the trendzone 11/05/20 01:03:31 PM
#66   * * $APVO Video Chart 11-04-2020 * * ClayTrader 11/04/20 06:05:54 PM
#65   LOOOOVE IT! Even better nobody even knows about PickleNick 11/04/20 05:02:17 PM
#64   GREAT MOVE ON APVO. APHA MOVING AFTERHOURS. otcmoneydoubler 11/04/20 04:45:37 PM
#63   * * $APVO Video Chart 11-03-2020 * * ClayTrader 11/03/20 06:05:23 PM
#62   GREAT APVO NEWS. ALSO OWCP BOOMING REST OF otcmoneydoubler 11/03/20 02:53:42 PM
#61   News; $APVO Aptevo Therapeutics Announces First Complete Remission whytestocks 11/03/20 12:15:27 PM
#60   News: $APVO Aptevo Therapeutics Reports Second Quarter 2020 whytestocks 08/14/20 08:00:09 PM
#59   News: $APVO Aptevo Therapeutics Collects $750,000 Working Capital whytestocks 06/29/20 10:15:18 PM
#58   * * $APVO Video Chart 06-25-2020 * * ClayTrader 06/25/20 06:01:52 PM
#57   * * $APVO Video Chart 05-11-2020 * * ClayTrader 05/11/20 05:31:44 PM
#56   * * $APVO Video Chart 03-11-2020 * * ClayTrader 03/11/20 06:08:06 PM
#55   expect stock to go lower edwardport 02/14/20 07:04:58 AM
#54   That's interesting, I had not been aware of ConstitutionNow 12/24/19 11:34:57 AM
#53   I had invested but ultimately sold my shares Fitz1030 12/24/19 09:53:18 AM
#52   I've been watching a bit, appears they are ConstitutionNow 12/24/19 01:11:29 AM
#51   Anybody still watching this one? Seems someone Fitz1030 11/11/19 05:40:33 PM
#50   APVO - .66 http://schrts.co/FGapdXfH Golf4Food 10/22/19 06:27:53 PM
#49   APVO waking up with good news backing this one. Earlofsandwich 10/03/19 06:27:01 PM
#48   I'm with this stock APVO because have a pfelgueiras 08/09/19 11:41:46 AM
#47   How high can this go? Maybe a partnership, J_Dean 06/20/19 10:52:40 AM
#46   They're supposed to release international licensing news soon. Warchest 06/20/19 10:43:56 AM
#45   News: $APVO Aptevo Therapeutics to Present New Preclinical whytestocks 03/25/19 02:20:35 PM
#44   Special Report on Immunology & Autoimmunity: Turn of Titan V 03/17/19 11:17:46 AM
#43   Most of the Float is being accumulated VERITAS77 03/08/19 07:40:47 PM
#42   $1.61 CASH share?! according to ... VERITAS77 03/07/19 10:53:21 PM
#41   News: $APVO Aptevo Announces Proposed Public Offering of whytestocks 03/06/19 04:50:33 PM
#40   Aptevo Therapeutics Announces IND Submission for APVO436 Golden_Cross 05/11/18 04:27:54 AM
#39   New Preclinical Data for Novel Immunotherapy Bispecific Candidate Golden_Cross 05/11/18 04:26:42 AM
#38   APVO Cheat Sheet Golden_Cross 05/11/18 04:25:03 AM
#37   New 52 Week High Yesterday Golden_Cross 05/11/18 04:23:51 AM
#36   Looks like back to $2.00 willlbone 01/17/18 07:15:39 AM
#35   I'm sure it burned through a heap of IveBeenBagged 01/16/18 11:05:08 PM
#34   Back to reality. willlbone 01/16/18 11:19:04 AM
#33   getting close to a 3yr high here, 3.75 tayronachan 12/06/17 02:44:38 PM
Consent Preferences